Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes.

Baranova EV, Verhoef TI, Ragia G, le Cessie S, Asselbergs FW, de Boer A, Manolopoulos VG, Maitland-van der Zee AH; EU-PACT group.

J Thromb Haemost. 2017 Mar;15(3):465-472. doi: 10.1111/jth.13615. Epub 2017 Feb 17.

PMID:
28063245
2.

Age-stratified outcome of a genotype-guided dosing algorithm for acenocoumarol and phenprocoumon.

Zhang Y, de Boer A, Verhoef TI, van der Meer FJ, Le Cessie S, Manolopoulos VG, Maitland-van der Zee AH; EU-PACT group.

J Thromb Haemost. 2017 Mar;15(3):454-464. doi: 10.1111/jth.13601. Epub 2017 Feb 17.

PMID:
27992949
3.

Comparison of dosing algorithms for acenocoumarol and phenprocoumon using clinical factors with the standard care in the Netherlands.

Zhang Y, de Boer A, Verhoef TI, van der Meer FJ, Le Cessie S, Maitland-van der Zee AH; EU-PACT group; members of the EU-PACT group are.

Thromb Res. 2015 Jul;136(1):94-100. doi: 10.1016/j.thromres.2015.04.034. Epub 2015 May 2.

PMID:
25971661
4.

Economic evaluation of a pharmacogenetic dosing algorithm for coumarin anticoagulants in The Netherlands.

Verhoef TI, Redekop WK, de Boer A, Maitland-van der Zee AH; EU-PACT group.

Pharmacogenomics. 2015 Jan;16(2):101-14. doi: 10.2217/pgs.14.149.

PMID:
25616097
5.

Genotype-guided dosing of vitamin K antagonists.

Maitland-van der Zee AH, de Boer A, Manolopoulos VG; EU-PACT Group.

N Engl J Med. 2014 May 1;370(18):1765-6. No abstract available.

PMID:
24804306
6.

Genotype-guided dosing of vitamin K antagonists.

Pirmohamed M, Wadelius M, Kamali F; EU-PACT Group.

N Engl J Med. 2014 May 1;370(18):1764-5. No abstract available.

PMID:
24804303
7.

Beliefs about medicines in Dutch acenocoumarol and phenprocoumon users.

Verhoef TI, Redekop WK, Bouvy ML, Dorenbos B, Karwar Z, van Schie RM, de Boer A, Maitland-van der Zee AH; EU-PACT group.

Br J Clin Pharmacol. 2014 Aug;78(2):422-9. doi: 10.1111/bcp.12346.

8.

A randomized trial of genotype-guided dosing of warfarin.

Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, Kesteven P, Christersson C, Wahlström B, Stafberg C, Zhang JE, Leathart JB, Kohnke H, Maitland-van der Zee AH, Williamson PR, Daly AK, Avery P, Kamali F, Wadelius M; EU-PACT Group.

N Engl J Med. 2013 Dec 12;369(24):2294-303. doi: 10.1056/NEJMoa1311386. Epub 2013 Nov 19.

9.

A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon.

Verhoef TI, Ragia G, de Boer A, Barallon R, Kolovou G, Kolovou V, Konstantinides S, Le Cessie S, Maltezos E, van der Meer FJ, Redekop WK, Remkes M, Rosendaal FR, van Schie RM, Tavridou A, Tziakas D, Wadelius M, Manolopoulos VG, Maitland-van der Zee AH; EU-PACT Group.

N Engl J Med. 2013 Dec 12;369(24):2304-12. doi: 10.1056/NEJMoa1311388. Epub 2013 Nov 19.

10.

Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation.

Verhoef TI, Redekop WK, Veenstra DL, Thariani R, Beltman PA, van Schie RM, de Boer A, Maitland-van der Zee AH; EU-PACT Group.

Pharmacogenomics. 2013 Jun;14(8):869-83. doi: 10.2217/pgs.13.74.

PMID:
23746182
11.

Long-term anticoagulant effects of CYP2C9 and VKORC1 genotypes in phenprocoumon users.

Verhoef TI, Redekop WK, Hegazy H, de Boer A, Maitland-van der Zee AH; EU-PACT group.

J Thromb Haemost. 2012 Dec;10(12):2610-2. doi: 10.1111/jth.12007. No abstract available.

12.

Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs.

Verhoef TI, Redekop WK, van Schie RM, Bayat S, Daly AK, Geitona M, Haschke-Becher E, Hughes DA, Kamali F, Levin LÅ, Manolopoulos VG, Pirmohamed M, Siebert U, Stingl JC, Wadelius M, de Boer A, Maitland-van der Zee AH; EU-PACT group.

Pharmacogenomics. 2012 Sep;13(12):1405-17. Review.

PMID:
22966889
13.

Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users.

Verhoef TI, Redekop WK, Buikema MM, Schalekamp T, Van Der Meer FJ, Le Cessie S, Wessels JA, Van Schie RM, De Boer A, Teichert M, Visser LE, Maitland-Van Der Zee AH; EU-PACT Group.

J Thromb Haemost. 2012 Apr;10(4):606-14. doi: 10.1111/j.1538-7836.2012.04633.x.

14.

A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives.

Verhoef TI, Redekop WK, Darba J, Geitona M, Hughes DA, Siebert U, de Boer A, Maitland-van der Zee AH, Barallon R, Briz M, Daly A, Haschke-Becher E, Kamali F, Kirchheiner J, Manolopoulos VG, Pirmohamed M, Rosendaal FR, van Schie RM, Wadelius M; EU-PACT Group.

Pharmacogenomics. 2010 Jul;11(7):989-1002. doi: 10.2217/pgs.10.74. Review.

PMID:
20602617

Supplemental Content

Loading ...
Support Center